U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257978) titled 'Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome' on July 18.
Brief Summary: The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design. RTT is a devastating rare genetic condition affecting females and involves debilitating physical and intellectual symptoms. NTI164 is an oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT, autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicat...